An association between Epstein-Barr Virus (EBV) infection and lymphoproliferative diseases has been reported with EBV + diffuse large B cell-lymphoma (DLBCL) of the elderly described as a distinct entity. In a cohort of 218 human immunodeficiency virus (HIV)-negative patients with diffuse large B-cell lymphomas, we detected EBV-DNA in 25% of whole blood (WB) samples at diagnosis. Presence and viral load in WB, mononuclear cells or plasma did not predict the presence of EBV in the tumor biopsy. Positive Hepatitis C virus (HCV) serology was associated with a higher frequency of EBV in WB. Patients with EBV-DNA in WB had a significantly shorter progression-free (p = 0.02) and overall survival (p = 0.05) after immunochemotherapy with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone). We conclude that detection of EBV in WB is not a surrogate marker for EBV-association in diffuse large B-cell lymphoma, however it associates with worse outcome.

Tisi, M. C., Cupelli, E., Santangelo, R., Maiolo, E., Alma, E., Giachelia, M., Martini, M., Bellesi, S., D'alo', F., Voso, M. T., Pompili, M., Leone, G., Larocca, L. M., Hohaus, S., Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma, <<LEUKEMIA & LYMPHOMA>>, 2015; 57 (3): 628-634. [doi:10.3109/10428194.2015.1072766] [http://hdl.handle.net/10807/87113]

Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma

Tisi
Primo
;
Maria Chiara; Cupelli
Secondo
;
Elisa; Santangelo;Rosaria; Maiolo;Elena; Alma;Eleonora; Giachelia;Manuela; Martini;Maurizio; Bellesi;Silvia; D'Alo';Francesco; Voso;Maria Teresa; Pompili;Maurizio; Leone;Giuseppe; Larocca
Penultimo
;
Luigi Maria; Hohaus
Ultimo
2016

Abstract

An association between Epstein-Barr Virus (EBV) infection and lymphoproliferative diseases has been reported with EBV + diffuse large B cell-lymphoma (DLBCL) of the elderly described as a distinct entity. In a cohort of 218 human immunodeficiency virus (HIV)-negative patients with diffuse large B-cell lymphomas, we detected EBV-DNA in 25% of whole blood (WB) samples at diagnosis. Presence and viral load in WB, mononuclear cells or plasma did not predict the presence of EBV in the tumor biopsy. Positive Hepatitis C virus (HCV) serology was associated with a higher frequency of EBV in WB. Patients with EBV-DNA in WB had a significantly shorter progression-free (p = 0.02) and overall survival (p = 0.05) after immunochemotherapy with R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone). We conclude that detection of EBV in WB is not a surrogate marker for EBV-association in diffuse large B-cell lymphoma, however it associates with worse outcome.
Inglese
Tisi, M. C., Cupelli, E., Santangelo, R., Maiolo, E., Alma, E., Giachelia, M., Martini, M., Bellesi, S., D'alo', F., Voso, M. T., Pompili, M., Leone, G., Larocca, L. M., Hohaus, S., Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma, <<LEUKEMIA & LYMPHOMA>>, 2015; 57 (3): 628-634. [doi:10.3109/10428194.2015.1072766] [http://hdl.handle.net/10807/87113]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/87113
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 21
social impact